FQ
UTHR icon

First Quadrant’s United Therapeutics UTHR Stock Holding History

First Quadrant’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-400
Closed -$40K – 675
2020
Q3 		$40K Sell
400
-784
-66% -$86K 0.01% 504
2020
Q2 		$143K Sell
1,184
-516
-30% -$58.1K 0.02% 473
2020
Q1 		$161K Hold
1,700
– – 0.02% 405
2019
Q4 		$150K Sell
1,700
-4,600
-73% -$405K 0.01% 433
2019
Q3 		$502K Hold
6,300
– – 0.05% 309
2019
Q2 		$492K Sell
6,300
-957
-13% -$89.5K 0.03% 402
2019
Q1 		$852K Buy
7,257
+957
+15% +$112K 0.07% 285
2018
Q4 		$686K Hold
6,300
– – 0.06% 299
2018
Q3 		$806K Hold
6,300
– – 0.02% 415
2018
Q2 		$713K Hold
6,300
– – 0.01% 446
2018
Q1 		$708K Hold
6,300
– – 0.01% 438
2017
Q4 		$932K Hold
6,300
– – 0.02% 450
2017
Q3 		$738K Sell
6,300
-118,596
-95% -$15.1M 0.01% 494
2017
Q2 		$16.2M Buy
124,896
+16,569
+15% +$2.07M 0.32% 108
2017
Q1 		$14.7M Sell
108,327
-36,743
-25% -$5.57M 0.29% 136
2016
Q4 		$20.8M Sell
145,070
-13,186
-8% -$1.68M 0.43% 77
2016
Q3 		$18.7M Buy
158,256
+151,956
+2,412% +$18.3M 0.4% 79
2016
Q2 		$667K Hold
6,300
– – 0.01% 452
2016
Q1 		$702K Sell
6,300
-66,800
-91% -$8.45M 0.02% 450
2015
Q4 		$11.4M Hold
73,100
– – 0.25% 124
2015
Q3 		$9.59M Sell
73,100
-1,500
-2% -$241K 0.21% 137
2015
Q2 		$13M Hold
74,600
– – 0.27% 118
2015
Q1 		$12.9M Sell
74,600
-14,900
-17% -$2.27M 0.27% 115
2014
Q4 		$11.6M Buy
89,500
+74,600
+501% +$9.61M 0.24% 123
2014
Q3 		$1.92M Sell
14,900
-191,700
-93% -$19.8M 0.04% 298
2014
Q2 		$18.3M Sell
206,600
-44,200
-18% -$4.25M 0.41% 73
2014
Q1 		$23.6M Sell
250,800
-20,300
-7% -$2.08M 0.54% 53
2013
Q4 		$30.7M Buy
271,100
+56,000
+26% +$5.05M 0.72% 36
2013
Q3 		$17M Buy
215,100
+44,800
+26% +$3.27M 0.43% 75
2013
Q2 		$11.2M Buy
+170,300
New +$11M 0.3% 99

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

First Quadrant's UTHR Position: Q4 2020 in Review

First Quadrant sold out of United Therapeutics (UTHR) in Q4 2020, closing a stake of 400 shares — an estimated $40K sold.

First Quadrant first reported a position in UTHR in Q2 2013 and held it in 30 quarters. The position peaked at $30.7M in Q4 2013. 356 funds tracked by Wall St. Rank hold UTHR as of Q4 2020.

  • First Quadrant reported no remaining United Therapeutics position as of Q4 2020 after selling out during the quarter.
  • First Quadrant sold 400 United Therapeutics shares in Q4 2020, an estimated $40K.
  • First Quadrant first reported a position in United Therapeutics in Q2 2013 and held it in 30 quarters.
  • First Quadrant's United Therapeutics position peaked at $30.7M in Q4 2013.
  • 356 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2020.

Based on First Quadrant's 13F filing for Q4 2020, filed 27 Jan 2021.